Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023)
Mira Pharmaceuticals (MIRA) posted Total Non-Current Liabilities of $558097.0 for Q4 2023, down 58.79% sequentially from $1.4 million in Q4 2022, and down 58.79% YoY from $1.4 million in Q4 2022.
Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of Total Non-Current Liabilities data on file, last reported at $558097.0 in Q4 2023.
- Quarterly Total Non-Current Liabilities fell 58.79% year-over-year to $558097.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $558097.0 (down 58.79% YoY) and the FY2023 annual result came in at $558097.0, down 58.79% from the prior year.
- Total Non-Current Liabilities eased to $558097.0 in Q4 2023 per MIRA's latest filing, from $1.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.4 million in Q4 2022, with the low at $558097.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 48.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.22 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 109.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -34.06 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 75.17 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 558,097.00 |
| Dec 31, 2022 | 1.35 Mn |